Abstract: The present invention relates to an oral solid dosage form comprising N2-{[1-ethyl-6-(4-methylphenoxy)-1H-benzimidazol-2-yl]methyl}-L-alaninamide, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof as an active ingredient, which has good dissolution and storage-stability. When the oral solid dosage form is a tablet, the tablet can be prepared while inhibiting tableting troubles from low content to high content of the active ingredient.

Abstract: A carbonated aerosol external preparation for skin, including a stock solution containing the following components (A) to (D) and a propellant including the following component (E): (A) a ceramide lipid, (B) an ionic surfactant, (C) a water-soluble polymer, (D) water, (E) carbon dioxide gas. A content of the component (A) in the stock solution is from 0.075 to 5.0% by mass, and a content of the component (B) in the stock solution is from 0.05 to 2.0% by mass, based on a total mass of the stock solution. A mass ratio of the component (C) to the component (B), (C)/(B), in the stock solution, is from 0.20 to 1.5.

Abstract: A carbonated aerosol external preparation for skin, including a stock solution containing the following components (A) to (C), and a propellant containing the following component (D): (A) heparinoid, (B) water-soluble polymer, (C) water, and (D) carbon dioxide gas. The carbonated aerosol external preparation for skin has a pH immediately after discharge of 4.0 or more and 7.0 or less. The component (B) includes one or more selected from the group consisting of hydroxypropylmethylcellulose and acrylic acid/alkyl (meth)acrylate copolymer. A content of the component (B) in the stock solution is from 0.05 to 5.0% by mass, based on a total mass of the stock solution.

Abstract: An external skin preparation comprises the following components (A) to (E), wherein the mass ratio of the component (A) to the component (B), (A)/(B), is from 0.3 to 2.0, wherein the content of the component (C) is from 0.1 to 1 mass %, and wherein the preparation has a pH at 25° C. of from 4.0 to 7.0: (A) one or more selected from the group consisting of aliphatic alcohols having from 14 to 20 carbon atoms; (B) two or more selected from the group consisting of polyhydric alcohol fatty acid ester-type nonionic surfactants; (C) one or more selected from the group consisting of N-acyl amino acids, N-acyl taurine, salts thereof, and phospholipids; (D) one or more selected from the group consisting of steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory drugs, and heparinoids; and (E) water.

Abstract: To provide a drug, an external use composition, and a cosmetic composition, which exhibit an NFAT signal inhibitory action, a calcineurin inhibitory action, and a hair growth-promoting effect. The NFAT signal inhibitor contains, as an active ingredient, American angelica or an extract thereof.

Abstract: To provide a drug, an external use composition, and a cosmetic composition, which exhibit an NFAT signal inhibitory action, a calcineurin inhibitory action, and a hair growth promoting effect. The NFAT signal inhibitor contains, as an active ingredient, American angelica or an extract thereof.

Abstract: To provide a drug, an external use composition, and a cosmetic composition, which exhibit an NFAT signal inhibitory action, a calcineurin inhibitory action, and a hair growth-promoting effect. The NFAT signal inhibitor contains, as an active ingredient, American angelica or an extract thereof.

Abstract: To provide a drug, an external use composition, and a cosmetic composition, which exhibit an NFAT signal inhibitory action, a calcineurin inhibitory action, and a hair growth-promoting effect. The NFAT signal inhibitor contains, as an active ingredient, American angelica or an extract thereof.